InDevR's FluChip detects and distinguishes swine-origin H1N1 from human influenza viruses

Boulder 05 May 2009InDevR, a small biotech company in Boulder, Colorado, and the Influenza Division of the Centers for Disease Control and Prevention (CDC) in Atlanta have confirmed that the M-gene version of InDevR's FluChip can detect swine-origin H1N1 influenza A viruses and clearly distinguish them from seasonal influenza viruses (A/H1N1 and A/H3N2) as well as the deadly avian A/H5N1 virus.

Advertisement

The FluChip was invented by a joint team of scientists at the University of Colorado at Boulder and the Centers for Disease Control and Prevention in an effort supported by the National Institute of Allergy and Infectious Diseases (NIAID) and led by then Professor Kathy Rowlen, CEO of InDevR. InDevR recently licensed the intellectual property from the University of Colorado and CDC.

The CDC provided InDevR scientists with non-infectious genetic material from swine-origin influenza viruses. The FluChip performance was evaluated with several of these samples in a side-by-side comparison with seasonal human influenza viruses.

"The FluChip assay detected all of the 6 swine-origin H1N1 viruses tested, and the resulting pattern, or signature, on the micro-array was dramatically different than the signature for seasonal A/H1N1 and A/H3N2 viruses. Interestingly, the signature of the swine H1N1 virus indicated an avian component within the M-gene, which is consistent with its reported Eurasian lineage", stated Dr. Erica Dawson, the Lead Scientist on the project at InDevR and co-inventor of the FluChip technology.

The FluChip is expected to be a powerful addition to the influenza surveillance toolkit since it will be less susceptible to failure than qRT-PCR assays as the virus continues to evolve. According to Kathy Rowlen the reason that the M-gene version of the FluChip is more robust has to do with the fact that the diagnostic target is a stable, internal gene which codes for the virus' matrix proteins. Current qRT-PCR subtyping assays target a more highly mutable gene that codes for a protein, hemagglutinin (HA), which is subject to antigenic drift.

"As has happened in the past, if the HA gene changes in a critical region, qRT-PCR will fail and the researcher won't know why until the gene is re-sequenced", stated Kathy Rowlen.

Based on these early FluChip results and with support from NIAID, part of the National Institutes of Health (NIH), InDevR will immediately begin manufacturing FluChip Kits for placement in a limited number of State Public Health labs. The Colorado Department of Public Health and Environment (CDPHE) will be the first site to receive FluChip assays for use as a complement to the newly released swine qRT-PCR assay.

"We are excited about helping to evaluate the FluChip technology. The ability to rapidly and reliably determine whether or not an influenza virus is seasonal or extraordinary would be tremendous", stated Dr. Hugh Maguire, Programme Manager of Microbiology and Molecular Science at the CDPHE.

InDevR will combine the FluChip technology with an innovative detection technology (NESA), which InDevR also licensed from the University of Colorado and further developed with NIAID support, to make the FluChip assay inexpensive and easy to use in any lab that has basic PCR capabilities.

InDevR is a small, privately held biotechnology company in Boulder, Colorado. Founded in 2003, InDevR employs a highly motivated team of individuals dedicated to the development and commercialization of innovative technologies that will help fill gaps in the current paradigm for virus-related diagnostics.


Source: University of Colorado at Boulder

[Medical IT News][Calendar][Virtual Medical Worlds Community][News on Advanced IT]